Immuron Ltd ADR (IMRN)

$0.80 -0.03 (-3.02%)
Market Cap 6.78M
Revenue (ttm) 4.72M
Net Income (ttm) -3.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -71.61%
Debt to Equity Ratio 0.00
Volume 2,500
Avg Vol 27,176
Day's Range N/A - N/A
Shares Out 8.17M
Stochastic %K 42%
Beta 0.87
Analysts Strong Buy
Price Target $5.00

Company Profile

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune su...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9824 5254
Fax: 61 3 9822 7735
Address:
62 Lygon Street, Level 3 Carlton South, Carlton, Australia
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 30 at 11:29 PM
$IMRN RSI: 53.52, MACD: 0.0128 Vol: 0.05, MA20: 0.85, MA50: 0.80 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Vinniesb
Vinniesb Apr. 23 at 6:18 PM
$IMRN
0 · Reply
Emerging_Growth_Research
Emerging_Growth_Research Apr. 22 at 9:50 PM
$IMRN Emerging Growth Research releases a flash report on $IMRN. Go here to read the full report: https://emerginggrowth.com/wp-content/uploads/2026/04/Immuron-Flash-Report-2026-04-22.pdf
0 · Reply
focafoca99
focafoca99 Apr. 22 at 6:39 PM
$IMRN Emerging Growth Research maintained its Buy-Extended rating and raised its price target to $4.00.
0 · Reply
Therhythmofstocks
Therhythmofstocks Apr. 21 at 11:29 AM
$IMRN give me $1.2 already
0 · Reply
MrACD
MrACD Apr. 19 at 4:15 PM
$IMRN $CMMB $SLS $ALT All I get from this post is to buy and hold $SLS because $SLS is very very
0 · Reply
cea
cea Apr. 19 at 4:00 PM
$ALT $CMMB $IMRN $SLS Why would anyone in $SLS give up an assured >2,000% payday in the short term for a maybe 200% payday who knows when? This is just silly. You have no credibility. Please take it somewhere else. I’m tempted to Report and Block you.
1 · Reply
Goldwave9
Goldwave9 Apr. 18 at 9:14 PM
$IMRN going to be huge, but...we're quite early. But that sure beats chasing those rockets in the pre market that wind up sinking into the ocean like an Iranian missile.
0 · Reply
t_baggin_u
t_baggin_u Apr. 17 at 10:29 AM
$IMRN https://www.globenewswire.com/news-release/2026/04/17/3276005/37134/en/Immuron-Double-Digit-3Q-Sales-Growth.html
0 · Reply
t_baggin_u
t_baggin_u Apr. 17 at 5:13 AM
$IMRN https://investors.immuron.com.au/announcements/7494849
0 · Reply
Latest News on IMRN
Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00

Wed, 22 Apr 2026 09:00:00 -0400 - 16 days ago

Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00

Immuron Double Digit 3Q Sales Growth

Fri, 17 Apr 2026 06:00:00 -0400 - 21 days ago

Immuron Double Digit 3Q Sales Growth

Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target

Thu, 05 Mar 2026 11:05:00 -0500 - 2 months ago

Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target

Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference

2026-03-05T11:00:00.000Z - 2 months ago

Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference

Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target

Thu, 22 Jan 2026 06:00:00 -0500 - 3 months ago

Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target

Immuron Reports Continued Sales Growth

Mon, 19 Jan 2026 06:00:00 -0500 - 3 months ago

Immuron Reports Continued Sales Growth

Why Is Immuron Stock (IMRN) Down Today?

2025-12-10T13:49:49.000Z - 5 months ago

Why Is Immuron Stock (IMRN) Down Today?

Immuron (IMRN) Collaborates on Vaccine Research with US Military Institutes

2025-12-03T11:53:11.000Z - 5 months ago

Immuron (IMRN) Collaborates on Vaccine Research with US Military Institutes

Immuron anounces new DoD award and clinical trial updates

2025-12-03T11:10:43.000Z - 5 months ago

Immuron anounces new DoD award and clinical trial updates

Immuron (IMRN) Secures FDA Approval for Phase 2 Trial of IMM-529

2025-11-05T11:58:49.000Z - 6 months ago

Immuron (IMRN) Secures FDA Approval for Phase 2 Trial of IMM-529

Immuron announces FDA approval of IND for IMM-529

2025-11-05T11:25:57.000Z - 6 months ago

Immuron announces FDA approval of IND for IMM-529

Immuron: FDA Approves IND Application For IMM-529

2025-11-05T11:25:02.000Z - 6 months ago

Immuron: FDA Approves IND Application For IMM-529

Immuron IMM-529 IND approved by FDA

Wed, 05 Nov 2025 06:00:00 -0500 - 6 months ago

Immuron IMM-529 IND approved by FDA

Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target

Fri, 17 Oct 2025 11:07:00 -0400 - 7 months ago

Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target

Immuron Announces Rise In Global Revenue For Q1

2025-10-13T12:54:51.000Z - 7 months ago

Immuron Announces Rise In Global Revenue For Q1

Immuron Q1 FY26 YoY growth

Mon, 13 Oct 2025 06:00:00 -0400 - 7 months ago

Immuron Q1 FY26 YoY growth

Immuron (IMRN) Seeks FDA Green Light for Novel C. diff Treatment

2025-10-08T11:31:48.000Z - 7 months ago

Immuron (IMRN) Seeks FDA Green Light for Novel C. diff Treatment

Why Immuron Is Rising In Pre-market?

2025-10-08T10:16:00.000Z - 7 months ago

Why Immuron Is Rising In Pre-market?

Immuron submitts IND application to FDA for clinical development of IMM-529

2025-10-08T10:05:07.000Z - 7 months ago

Immuron submitts IND application to FDA for clinical development of IMM-529

Immuron Submits IMM-529 IND to FDA

Wed, 08 Oct 2025 06:00:00 -0400 - 7 months ago

Immuron Submits IMM-529 IND to FDA

Immuron (IMRN) Updates Shareholders on Key Project Developments

2025-10-02T11:26:44.000Z - 7 months ago

Immuron (IMRN) Updates Shareholders on Key Project Developments

Immuron announces projects update

2025-10-02T10:20:08.000Z - 7 months ago

Immuron announces projects update

Immuron Letter to Shareholders – Projects Update

Thu, 02 Oct 2025 06:00:00 -0400 - 7 months ago

Immuron Letter to Shareholders – Projects Update

Immuron enters partnership with InvestorHub

2025-08-27T09:20:17.000Z - 9 months ago

Immuron enters partnership with InvestorHub

Immuron partners with InvestorHub

Tue, 26 Aug 2025 22:29:00 -0400 - 9 months ago

Immuron partners with InvestorHub

Immuron says FY25 global sales exceed projection, up 49% over prior year

2025-07-17T10:05:32.000Z - 10 months ago

Immuron says FY25 global sales exceed projection, up 49% over prior year

Immuron - FY25 global sales exceed projection, up 49% on prior year

Thu, 17 Jul 2025 06:00:00 -0400 - 10 months ago

Immuron - FY25 global sales exceed projection, up 49% on prior year

Immuron Letter to Shareholders: Projects Update

Fri, 30 May 2025 06:00:00 -0400 - 1 year ago

Immuron Letter to Shareholders: Projects Update

Immuron (IMRN) Achieves Record Sales Milestone

2025-04-11T08:55:40.000Z - 1 year ago

Immuron (IMRN) Achieves Record Sales Milestone

Immuron Travelan® highest sales in history

Thu, 10 Apr 2025 18:00:00 -0400 - 1 year ago

Immuron Travelan® highest sales in history

Immuron partners with Calmino to distribute ProIBS in Australia, New Zealand

2025-03-05T11:06:32.000Z - 1 year ago

Immuron partners with Calmino to distribute ProIBS in Australia, New Zealand

Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)

Wed, 05 Mar 2025 06:00:00 -0500 - 1 year ago

Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)

Immuron reports strong sales growth of Travelan

2025-01-17T11:10:11.000Z - 1 year ago

Immuron reports strong sales growth of Travelan

Immuron Travelan® continued strong sales growth

Fri, 17 Jan 2025 06:00:00 -0500 - 1 year ago

Immuron Travelan® continued strong sales growth

Immuron announces research collaboration agreement with Monash University

2025-01-15T11:05:46.000Z - 1 year ago

Immuron announces research collaboration agreement with Monash University

Immuron Announces New Research Collaboration targeting Antimicrobial Resistance

Wed, 15 Jan 2025 06:00:00 -0500 - 1 year ago

Immuron Announces New Research Collaboration targeting Antimicrobial Resistance

Immuron announces Travelan clinical trial update

2025-01-14T11:10:34.000Z - 1 year ago

Immuron announces Travelan clinical trial update

Immuron Announces Travelan® Clinical Trial Update

Tue, 14 Jan 2025 06:00:00 -0500 - 1 year ago

Immuron Announces Travelan® Clinical Trial Update

Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th

Mon, 02 Dec 2024 06:00:00 -0500 - 1 year ago

Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th

Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event

Thu, 21 Nov 2024 18:33:00 -0500 - 1 year ago

Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event

Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event

Mon, 18 Nov 2024 08:30:00 -0500 - 1 year ago

Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event

Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference

Wed, 16 Oct 2024 06:00:00 -0400 - 1 year ago

Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference

Immuron reports Q3 sales of Travelan up 13% vs. Q2

2024-10-15T10:10:20.000Z - 1 year ago

Immuron reports Q3 sales of Travelan up 13% vs. Q2

Immuron Travelan® continued strong sales growth

Tue, 15 Oct 2024 06:00:00 -0400 - 1 year ago

Immuron Travelan® continued strong sales growth

Immuron says NMRC completes interim analysis for evaluation in Campylobacter

2024-10-05T09:06:00.000Z - 1 year ago

Immuron says NMRC completes interim analysis for evaluation in Campylobacter

NMRC Reports Results for Campylobacter Controlled Human Infection Model Study

Fri, 04 Oct 2024 06:30:00 -0400 - 1 year ago

NMRC Reports Results for Campylobacter Controlled Human Infection Model Study

Immuron trading halted, news pending

2024-10-02T23:10:07.000Z - 1 year ago

Immuron trading halted, news pending

Immuron initiated with a Buy at Litchfield Hills

2024-09-26T13:25:16.000Z - 1 year ago

Immuron initiated with a Buy at Litchfield Hills

Traveler's Diarrhea Therapeutics Pipeline Market Report 2024 Featuring Immuron, Scandinavian Biopharma, and Sigmoid Pharma

Thu, 19 Sep 2024 09:42:00 -0400 - 1 year ago

Traveler's Diarrhea Therapeutics Pipeline Market Report 2024 Featuring Immuron, Scandinavian Biopharma, and Sigmoid Pharma

Immuron Ltd Webinar Presentation Transcript

2024-09-14T11:17:07.000Z - 1 year ago

Immuron Ltd Webinar Presentation Transcript

Immuron plans Phase 2 trial for IMM-529 following FDA review

2024-09-05T16:00:45.000Z - 1 year ago

Immuron plans Phase 2 trial for IMM-529 following FDA review

Immuron Plans Phase 2 Trial for IMM-529 following FDA review

Sep 5, 2024, 11:54 AM EDT - 1 year ago

Immuron Plans Phase 2 Trial for IMM-529 following FDA review

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD ELUT EUDA GDTC GOSS GOVX

Immuron announces new DoD research award for NMRC

2024-08-16T10:02:59.000Z - 1 year ago

Immuron announces new DoD research award for NMRC

Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®

Aug 16, 2024, 6:00 AM EDT - 1 year ago

Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®

Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference

Aug 15, 2024, 6:14 PM EDT - 1 year ago

Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference

Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect

Aug 7, 2024, 6:00 AM EDT - 1 year ago

Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect

Immuron announces record Travelen sales globally

2024-07-15T12:10:03.000Z - 1 year ago

Immuron announces record Travelen sales globally

Immuron requests pre-IND meeting for IMM-529 with FDA filing

Jul 2, 2024, 6:00 AM EDT - 2 years ago

Immuron requests pre-IND meeting for IMM-529 with FDA filing

Immuron Board Changes

May 31, 2024, 6:00 AM EDT - 2 years ago

Immuron Board Changes

Immuron CEO Steven Lydeamore to present at Peak Sky High

May 31, 2024, 6:00 AM EDT - 2 years ago

Immuron CEO Steven Lydeamore to present at Peak Sky High

Immuron Limited to Present at the Emerging Growth Conference

May 7, 2024, 6:00 AM EDT - 2 years ago

Immuron Limited to Present at the Emerging Growth Conference

Immuron Director Resignation

May 3, 2024, 6:00 AM EDT - 2 years ago

Immuron Director Resignation

Immuron to host Live Virtual Event

Apr 15, 2024, 6:00 AM EDT - 2 years ago

Immuron to host Live Virtual Event

Immuron Travelan® sales continued strong growth

Apr 10, 2024, 6:00 AM EDT - 2 years ago

Immuron Travelan® sales continued strong growth

Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US

Mar 7, 2024, 6:00 AM EST - 2 years ago

Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US

Immuron Presentation Australian Biologics Festival 2024

Feb 21, 2024, 6:00 AM EST - 2 years ago

Immuron Presentation Australian Biologics Festival 2024

Immuron achieves record Travelan® sales

Feb 13, 2024, 6:00 AM EST - 2 years ago

Immuron achieves record Travelan® sales

Immuron CEO, Steven Lydeamore Investor Webinar Presentation

Feb 8, 2024, 6:00 AM EST - 2 years ago

Immuron CEO, Steven Lydeamore Investor Webinar Presentation

Immuron achieves record half yearly Travelan® sales

Jan 16, 2024, 6:00 AM EST - 2 years ago

Immuron achieves record half yearly Travelan® sales

Immuron Clinical Trials Update

Dec 22, 2023, 6:00 AM EST - 2 years ago

Immuron Clinical Trials Update

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Dec 4, 2023, 6:00 AM EST - 2 years ago

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Immuron CEO Steven Lydeamore Investor Webinar Presentation

Nov 13, 2023, 6:00 PM EST - 2 years ago

Immuron CEO Steven Lydeamore Investor Webinar Presentation

Immuron CEO Steven Lydeamore presented at AusBioInvest

Oct 30, 2023, 7:21 AM EDT - 2 years ago

Immuron CEO Steven Lydeamore presented at AusBioInvest

Immuron Announces Travelan® Clinical Study Cohort 2 commences

Oct 18, 2023, 6:00 AM EDT - 2 years ago

Immuron Announces Travelan® Clinical Study Cohort 2 commences

Immuron achieves record quarterly Travelan® sales

Oct 11, 2023, 6:00 AM EDT - 2 years ago

Immuron achieves record quarterly Travelan® sales

Immuron Limited Announces Participation in the LD Micro Main Event XVI

Sep 18, 2023, 7:30 AM EDT - 2 years ago

Immuron Limited Announces Participation in the LD Micro Main Event XVI

Immuron achieves record monthly Travelan® sales

Sep 13, 2023, 6:00 AM EDT - 2 years ago

Immuron achieves record monthly Travelan® sales

Immuron CEO, Steven Lydeamore to present at H.C. Wainwright

Sep 11, 2023, 6:00 AM EDT - 2 years ago

Immuron CEO, Steven Lydeamore to present at H.C. Wainwright

OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 30 at 11:29 PM
$IMRN RSI: 53.52, MACD: 0.0128 Vol: 0.05, MA20: 0.85, MA50: 0.80 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Vinniesb
Vinniesb Apr. 23 at 6:18 PM
$IMRN
0 · Reply
Emerging_Growth_Research
Emerging_Growth_Research Apr. 22 at 9:50 PM
$IMRN Emerging Growth Research releases a flash report on $IMRN. Go here to read the full report: https://emerginggrowth.com/wp-content/uploads/2026/04/Immuron-Flash-Report-2026-04-22.pdf
0 · Reply
focafoca99
focafoca99 Apr. 22 at 6:39 PM
$IMRN Emerging Growth Research maintained its Buy-Extended rating and raised its price target to $4.00.
0 · Reply
Therhythmofstocks
Therhythmofstocks Apr. 21 at 11:29 AM
$IMRN give me $1.2 already
0 · Reply
MrACD
MrACD Apr. 19 at 4:15 PM
$IMRN $CMMB $SLS $ALT All I get from this post is to buy and hold $SLS because $SLS is very very
0 · Reply
cea
cea Apr. 19 at 4:00 PM
$ALT $CMMB $IMRN $SLS Why would anyone in $SLS give up an assured >2,000% payday in the short term for a maybe 200% payday who knows when? This is just silly. You have no credibility. Please take it somewhere else. I’m tempted to Report and Block you.
1 · Reply
Goldwave9
Goldwave9 Apr. 18 at 9:14 PM
$IMRN going to be huge, but...we're quite early. But that sure beats chasing those rockets in the pre market that wind up sinking into the ocean like an Iranian missile.
0 · Reply
t_baggin_u
t_baggin_u Apr. 17 at 10:29 AM
$IMRN https://www.globenewswire.com/news-release/2026/04/17/3276005/37134/en/Immuron-Double-Digit-3Q-Sales-Growth.html
0 · Reply
t_baggin_u
t_baggin_u Apr. 17 at 5:13 AM
$IMRN https://investors.immuron.com.au/announcements/7494849
0 · Reply
BonprixUltimateGuardians
BonprixUltimateGuardians Mar. 24 at 10:51 PM
Actually a good group of bulls below, they actually jumped in to some runners early💎 Check them out, Cool free group 👇🔥 Been swinging some $NAK $RZLT $IMRN $ADGM too
0 · Reply
peepthestamp
peepthestamp Mar. 6 at 8:23 PM
$IMRN
0 · Reply
Baseball89
Baseball89 Mar. 3 at 12:32 PM
$EHTH $IMRN keep watch. Profitable yr after yr.
0 · Reply
Baseball89
Baseball89 Feb. 27 at 5:51 PM
$BDSX $NCNA & $IMRN keep watch.Sleeping giant!!!
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 27 at 1:58 AM
$IMRN RSI: 57.17, MACD: -0.0454 Vol: 0.07, MA20: 0.78, MA50: 0.87 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Baseball89
Baseball89 Feb. 23 at 11:02 PM
$IMRN This could reach $80-$100 soon. Keep watch.
0 · Reply
LeonCleland213
LeonCleland213 Feb. 18 at 12:49 PM
$IMRN Biotech with long development horizon; dilution risk persistent.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 17 at 6:42 PM
$IMRN Current Stock Price: $0.74
0 · Reply
riskalex
riskalex Feb. 17 at 8:13 AM
$IMRN Pre-revenue biotech; early-stage pipeline
0 · Reply
Baseball89
Baseball89 Feb. 10 at 1:02 PM
$PHIO $IMRN ---keep watch.
0 · Reply
Baseball89
Baseball89 Feb. 10 at 12:05 PM
$LIMN $IMRN - profitable,low float,Travelan, US military. Keep watch.
0 · Reply
Baseball89
Baseball89 Feb. 10 at 11:11 AM
$IMRN let's get this one trending. Low float. Profitable year after year. PT $20
0 · Reply